Susan Day, APRN
Psychiatric/Mental Health · Boise, IDNPI 1134733694
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.0%), food and beverage and education — rather than concentrated in one kind of arrangement. Teva Pharmaceuticals USA, Inc. accounts for 64.3% of it on its own, with 14 other manufacturers making up the rest. 2025 is the largest year on record at $6,354, 7.9 times the $804 reported in 2022. Among psychiatric/mental health clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 180 payments — averaging $49.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$6K
- Neurocrine Biosciences, Inc.$988
- Alkermes, Inc.$439
- Otsuka America Pharmaceutical, Inc.$378
- AbbVie$351
- Johnson & Johnson$244
- plus $813 from 9 others
What the payments were for
- Speaking & faculty fees$5,04056%
- Travel & lodging$290%
- Food & beverage$3,69441%
- Education$2353%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 28 | $5,784 |
| Neurocrine Biosciences, Inc. | 36 | $988 |
| Alkermes, Inc. | 15 | $439 |
| Otsuka America Pharmaceutical, Inc. | 24 | $378 |
| AbbVie | 28 | $351 |
| Johnson & Johnson | 10 | $244 |
| E.r. Squibb & Sons, L.L.C. | 8 | $238 |
| Vanda Pharmaceuticals Inc. | 8 | $170 |
| Lundbeck LLC | 6 | $119 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $103 |
| Axsome Therapeutics, Inc. | 4 | $68 |
| Supernus Pharmaceuticals, Inc. | 2 | $39 |
| Corium, LLC | 3 | $37 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $20 |
| Indivior Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UZEDY$5,270
- LYBALVI$479
- INGREZZA$465
- COBENFY$131
- INVEGA SUSTENNA$100
How this compares
$8,998 in reported general payments places this provider in the 95th percentile of 221 psychiatric/mental health providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 70 | $249,220 |
| IngrezzaValbenazine Tosylate | 16 | $130,662 |
| VraylarCariprazine Hcl | 54 | $73,828 |
| AristadaAripiprazole Lauroxil | 20 | $71,097 |
| RexultiBrexpiprazole | 33 | $46,951 |
| CaplytaLumateperone Tosylate | 15 | $24,228 |
| QuviviqDaridorexant Hcl | 21 | $10,519 |
| Aripiprazole | 79 | $9,410 |
| TrintellixVortioxetine Hydrobromide | 14 | $7,954 |
| Lisdexamfetamine Dimesylate | 27 | $6,636 |
| Lurasidone Hcl | 28 | $6,269 |
| Olanzapine | 96 | $4,989 |
| Paliperidone ErPaliperidone | 21 | $4,025 |
| Ramelteon | 15 | $3,918 |
| Olanzapine OdtOlanzapine | 21 | $3,069 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $244 | $249,22070 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $988 | $130,66216 claims |
| AbbVieVraylar | $351 | $73,82854 claims |
| Alkermes, Inc.Aristada | $439 | $71,09720 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $378 | $46,95133 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $103 | $24,22815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 221 psychiatric/mental health providers in Idaho.
Other psychiatric/mental health in Boise
- Misti NewsonBoise$56K
- Carey CrillBoise$19K
- Julie SchraderBoise$9K
- Grace MensahBoise$6K
- Katie HarpBoise$6K
- Eliza SalazarBoise$5K
- Brigitta PantherBoise$5K
- Dawn LoceyBoise$3K
- Lisa BrynerBoise$3K
- Jenny PinsonBoise$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.